Prescription drug · NDA
Erivedge (Vismodegib) NDC 50242-140
Vismodegib 150 mg/1 · Capsule · Oral · Genentech, Inc.
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 50242-140-01 | 50242014001 | 1 BOTTLE, PLASTIC in 1 CARTON (50242-140-01) / 28 CAPSULE in 1 BOTTLE, PLASTICMarketed from Jan 30, 2012 | |
| 50242-140-86 | 50242014086 | 1 BOTTLE, PLASTIC in 1 CARTON (50242-140-86) / 28 CAPSULE in 1 BOTTLE, PLASTICMarketed from Apr 9, 2013 · Sample package |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Erivedge
- Generic name (nonproprietary)
- vismodegib
- Active ingredients
- Vismodegib — 150 mg/1
- Dosage form
- Capsule
- Route
- Oral
- Labeler
- Genentech, Inc.NDC labeler code 50242
- Product type
- Prescription drug
- Marketing category
- NDA — New Drug ApplicationApplication NDA 203388
- Marketing start
- Listing expires
- Other FDA classes
- Smoothened Receptor Antagonists (Mechanism)
- Identifiers
- Product ID 50242-140_d8b343ee-5767-4934-ad68-5164d4de5228SPL ID d8b343ee-5767-4934-ad68-5164d4de5228SPL set ID eb368bb6-80e3-4df9-8a85-91df0a2ada6aRxCUI 1242992, 1242998UNII 25X868M3DS
- Pharmacologic class
- Hedgehog Pathway Inhibitor
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N450242014001followed by a unit qualifier and the quantityPackage 50242-0140-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective . This label includes a boxed warning.
Indications (excerpt from the label)
ERIVEDGE is indicated for the treatment of adults with metastatic basal cell carcinoma, or with locally advanced basal cell carcinoma that has recurred following surgery or who are not candidates for surgery and who are not candidates for radiation. ERIVEDGE ® (vismodegib) is a hedgehog pathway inhibitor indicated for the treatment of adults with metastatic basal cell carcinoma, or with locally advanced basal cell carcinoma that has recurred following surgery or who are not candidates for surgery and who are not candidates for radiation. ( 1 )
Excerpt only. Read the full label for complete information.
About NDC 50242-140
- What is NDC 50242-140?
- 50242-140 is the product NDC for Erivedge (vismodegib), Vismodegib 150 mg/1 capsule, listed with the FDA by Genentech, Inc.. It has 2 package NDCs, shown above in 10- and 11-digit form.
- What drug is associated with this NDC?
- Erivedge (Vismodegib).
- What is the active ingredient?
- Vismodegib.
- Who is the labeler?
- Genentech, Inc., NDC labeler code 50242. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
- What other NDCs exist for Erivedge?
- None: this is the only finished product listed under this name.
- Is there a related HCPCS / J-code?
- Not in Med-Code's curated HCPCS directory. See Billing references above.